Comparative Pharmacology
Head-to-head clinical analysis: FARESTON versus MILOPHENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARESTON versus MILOPHENE.
FARESTON vs MILOPHENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
60 mg orally once daily.
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
None Documented
None Documented
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator